Aptevo Therapeutics Inc. (APVO): Price and Financial Metrics
APVO Price/Volume Stats
Current price | $4.69 | 52-week high | $92.62 |
Prev. close | $4.06 | 52-week low | $3.81 |
Day low | $3.95 | Volume | 304,500 |
Day high | $5.00 | Avg. volume | 102,554 |
50-day MA | $6.07 | Dividend yield | N/A |
200-day MA | $19.20 | Market Cap | 2.01M |
APVO Stock Price Chart Interactive Chart >
Aptevo Therapeutics Inc. (APVO) Company Bio
Aptevo Therapeutics, a biotechnology company, provides oncology and hematology therapeutics. Its marketed products include WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn; and HepaGam B used for the prevention of hepatitis-B recurrence following liver transplantation in HBsAg-positive liver transplant patients, and for the treatment following exposure to hepatitis-B. The company was spun off from Emergent BioSolutions Inc. in 2016 and is based in Seattle, Washington.
Latest APVO News From Around the Web
Below are the latest news stories about APTEVO THERAPEUTICS INC that investors may wish to consider to help them evaluate APVO as an investment opportunity.
Aptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business UpdateThe Company's ALG.APV-527 Phase 1 Trial for the Treatment of Multiple Solid Tumors Continues to ProgressPlanning for APVO436 Phase 2 Trial Initiation in Both Relapsed/Refractory and Frontline AML OngoingExtended Cash Runway with $7 Million in Funding ... |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayWe're closing out the trading week with a breakdown of the biggest pre-market stock movers worth watching for Friday morning! |
Aptevo to Present at Bio-Europe ConferenceSEATTLE, WA / ACCESSWIRE / November 1, 2023 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, ... |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayPre-market stock movers are a hot topic with investors this morning and we're checking out the biggest ones worth watching on Tuesday! |
Aptevo Therapeutics Reports 2Q23 Financial Results and Provides a Business UpdateAptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported financial results for the quarter ended June 30, 2023 and provided a business update, including duration of remission (DOR) data for its lead clinical candidate, APVO436. |
APVO Price Returns
1-mo | -31.54% |
3-mo | -41.11% |
6-mo | -67.70% |
1-year | -94.77% |
3-year | -99.62% |
5-year | -99.15% |
YTD | -41.11% |
2023 | -92.20% |
2022 | -70.52% |
2021 | -78.53% |
2020 | 299.98% |
2019 | -48.46% |
Continue Researching APVO
Here are a few links from around the web to help you further your research on Aptevo Therapeutics Inc's stock as an investment opportunity:Aptevo Therapeutics Inc (APVO) Stock Price | Nasdaq
Aptevo Therapeutics Inc (APVO) Stock Quote, History and News - Yahoo Finance
Aptevo Therapeutics Inc (APVO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...